OUKA
The University of Osaka
Institutional Knowledge Archive

Title	Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma
Author(s)	Maesaka, Kazuki; Hikita, Hayato; Tahata, Yuki et al.
Citation	Journal of Gastroenterology. 2025
Version Type	AM
URL	https://hdl.handle.net/11094/103018
rights	Maesaka K., Hikita H., Tahata Y., et al. Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma. Journal of Gastroenterology (2025); https://doi.org/10.1007/s00535-025-02308-x.
Note	

The University of Osaka Institutional Knowledge Archive : OUKA

https://ir.library.osaka-u.ac.jp/

The University of Osaka



Len after Atezo+Beva n = 85
1st line Len n = 182
Third or later line treatment n = 11
Without liver image using contrast media n = 2
More than 3 months after Atezo+Beva n = 3
PS ≥ 2 n = 2
Without liver image using contrast media n = 8
Comorbidity of other advanced cancers n = 2
After Atezo+Beva group n = 67 (2nd line)
1st line group n = 172
Propensity score matching
After Atezo+Beva group n = 63 (2nd line)
1st line group n = 63

Fig. 1



a
mRECIST
100%
80%
60%
40%
20%
0%
DCR
p=0.857
ORR
p=0.291
After Atezo+Beva
1st line
b
RECIST v1.1
100%
80%
60%
40%
20%
0%
DCR
p=1.000
ORR
p=0.609
After Atezo+Beva
1st line

Fig. 2



a
Progression-free survival (%)
100
80
60
40
20
0
p = 0.118
1st line: 5.5 months
After Atezo+Beva: 4.2 months
0
4
8
12
16
20
24
Time (months)
Patients at risk
1st line 172 95 47 16 6 1
After Atezo+Beva 67 27 8 2 1 1
b
Overall survival (%)
100
80
60
40
20
0
p = 0.082
1st line: 20.6 months
After Atezo+Beva: 14.0 months
0
6
12
18
24
30
36
42
Time (months)
Patients at risk
1st line 172 140 104 71 39 17 5 1
After Atezo+Beva 67 46 16 6

Fig. 3



a
mRECIST
100%
80%
60%
40%
20%
0%
DCR
p=0.655
ORR
p=0.455
After Atezo+Beva
1st line
b
RECIST v1.1
100%
80%
60%
40%
20%
0%
DCR
p=0.655
ORR
p=0.679
After Atezo+Beva
1st line

Fig. 4



a
Progression-free survival (%)
100
80
60
40
20
0
p = 0.233
1st line: 5.2 months
After Atezo+Beva: 4.5 months
0
4
8
12
16
20
24
Time (months)
Patients at risk
1st line 63 35 17 4 1
After Atezo+Beva 63 27 8 2 1 1
b
Overall survival (%)
100
80
60
40
20
0
p = 0.769
1st line: 16.0 months
After Atezo+Beva: 14.3 months
0
6
12
18
24
30
36
42
Time (months)
Patients at risk
1st line 63 48 34 23 11 4 1
After Atezo+Beva 63 44 16 6

Fig. 5